Pain relief drug for mast cell disorder fails to reach goal
NCT ID NCT05652907
First seen May 01, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tested whether FSD201 could reduce daily pain in adults with chronic widespread pain caused by mast cell activation syndrome. Only 2 people enrolled before the trial was stopped early. Participants took FSD201 or a placebo for up to 56 days and reported their pain levels. The main goal was a 30% pain reduction after 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAST CELL ACTIVATION SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Norman Marcus Pain Institute
New York, New York, 10016, United States
-
Saint Charles Clinical Research
Weldon Spring, Missouri, 63304, United States
-
Toronto Rehabilitation Institute
Toronto, Ontario, Canada
Conditions
Explore the condition pages connected to this study.